Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

Sansure Biotech’s Respiratory Adenovirus DNA Diagnostic Kit was approved for marketing
2022-03-10

The Respiratory Adenovirus DNA Diagnostic Kit (PCR-Fluorescence Probing) developed by Sansure was approved for marketing lately, adding another powerful tool to its total solution of respiratory nucleic acid test. Adenovirus, an easily neglected but dangerous respiratory infection pathogen Why is it dangerous and easily neglected? This is because adenovirus is also a virus that is strongly associated with respiratory diseases and […]

LEARN MORE
Sansure Biotech’s SARS-CoV-2 variant diagnostic kit received marketing authorization approval from Ministère des Solidarités et de la Santé (Ministry of Solidarity and Health)
2022-01-11

Sansure Biotech’s SARS-CoV-2 L452R/E484K/K417N Variant Diagnostic Kit received marketing authorization approval from Ministère des Solidarités et de la Santé (Ministry of Solidarity and Health) the other day. This is Sansure Biotech’s fifth SARS-CoV-2 detection product that has received marketing authorization approval from Ministère des Solidarités et de la Santé. The Omicron variant of SARS-CoV-2 is now spreading rapidly and rampantly […]

LEARN MORE
Sansure Biotech’s HPV DNA Diagnostic Kit (HPV 13+2) approved by the NMPA
2022-01-11

Sansure Biotech’s HPV DNA Diagnostic Kit (HPV 13+2) was approved by the China NMPA on January 6, with reference to the medical device approval released on the NMPA’s official website. This is another blockbuster product from Sansure Biotech in promoting the global elimination of cervical cancer. In 2020, WHO launched a global strategy to accelerate the elimination of cervical cancer, […]

LEARN MORE
Sansure Biotech’s SARS-CoV-2 Rapid Antigen Test Included in EU HSC Common List
2021-12-30

On December 21,  a SARS-CoV-2 Rapid Antigen Test (Colloidal Gold Method) developed by Sansure Biotech was included in EU Health Security Committee (HSC) Common List. Hence, the product has been accredited by yet another international certification body, following its CE certification and inclusion in the common lists of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) […]

LEARN MORE
Sansure Biotech’s SARS-CoV-2 and Influenza A/B Virus Nucleic Acid Diagnostic Kit was approved by China NMPA for marketing
2021-12-23

The kit developed by Sansure Biotech for nucleic acid detection of SARS-CoV-2, and influenza A & B virus (PCR-Fluorescence Probing) was approved by the National Medical Products Administration (NMPA) for marketing on December 17. It has also received CE mark and is expected to provide critical support for global COVID-19 prevention and control. According to WHO estimates, influenza causes 3 to 5 […]

LEARN MORE
×
Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.
SUBMIT

Thank you!

We shall contact you soon!
Back Top